GmPcide Program
Bacterial Infections (Gram-positive, e.g., MRSA, E. faecalis)
Pre-clinicalActive
Key Facts
Indication
Bacterial Infections (Gram-positive, e.g., MRSA, E. faecalis)
Phase
Pre-clinical
Status
Active
Company
About Quretech Bio
QureTech Bio is a preclinical-stage biotech tackling the global crisis of antimicrobial resistance (AMR) with a novel antivirulence strategy. The company's proprietary GmPcide compounds aim to disarm pathogenic bacteria by inhibiting key virulence mechanisms, potentially rendering resistant bacteria susceptible again to existing antibiotics. Founded on academic research from Umeå University, the company is building a portfolio supported by recent US patents and Swedish Research Council funding. Leadership combines deep scientific expertise in microbiology and chemistry with seasoned biotech industry experience.
View full company profile